In vivo potentiated formulation of eprosartan in solid oral dosage form

摘要

This invention relates to bioenhanced formulations comprising eprosartan or eprosartan mesylate in the amorphous form, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.